Are AIs for Breast Cancer Linked With Increased Myocardial Infarction Risk?

Video

This video examines a study that looked at whether aromatase inhibitors are associated with higher myocardial infarction risk in breast cancer patients.

In this video, Sailaja Kamaraju, MD, of the Medical College of Wisconsin, discusses a study that looked at whether aromatase inhibitors (AIs) are associated with higher myocardial infarction risk in breast cancer patients.

The study looked at 5,648 women (67 years and older) from the Surveillance, Epidemiology, and End Results–Medicare (SEER) database with stages I–III breast cancer who were treated with either AIs (n = 4,690) or tamoxifen (n = 958). With over 2 years follow-up there were 22 deaths from myocardial infarction (251 total cases), with 476 deaths from other causes.

Related Videos
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Related Content